갱년기 장애 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 지역별, 부문 예측(2025-2030년)

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (NA, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,788,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,265,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,220,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

갱년기 장애 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 갱년기 장애 시장 규모는 2025-2030년에 CAGR 5.42%를 기록하며, 2030년까지 243억 5,000만 달러에 달할 것으로 예측됩니다.

폐경 후 증후군 유병률 증가, 갱년기 관련 건강 인식 증가, 여성 건강 앱의 높은 채택률 등의 요인이 시장 성장을 촉진할 것으로 예측됩니다.

시장은 HRT에 대한 건강기능식품의 이점을 지지하는 연구가 증가함에 따라 견인될 것으로 예측됩니다. 블랙코호시, 레드 클로버, 대두 이소플라본, 암베렌 등의 성분을 포함한 많은 건강 보조 식품이 시중에서 판매되고 있습니다. 제조업체들 역시 갱년기 증상에 대응하는 신제품 개발에 힘쓰고 있습니다. 예를 들어 몰파스(Morphas)는 2023년에 갱년기 및 갱년기 장애의 가장 시급한 증상 중 일부에 대응하기 위한 몇 가지 보충제를 출시했습니다. 첫 번째 제품은 FiberUs로, 구아 섬유로 만든 무향의 수용성 프리바이오틱 섬유입니다.

건강기능식품 및 OTC 의약품에 대한 수요는 의사 예약 지연, 호르몬 대체요법의 재연기, 소매 약국 및 온라인 채널에서 OTC 의약품을 쉽게 구할 수 있게 됨에 따라 포스트 팬데믹 시나리오에서 증가했습니다. 그러나 규제 완화와 갱년기 질환에 대한 인식이 높아짐에 따라 시장은 현재 안정화되고 있습니다.

2023년 5월, FDA는 갱년기 여성들이 갱년기에 자주 경험하는 안면홍조와 식은땀을 치료하기 위한 새로운 비호르몬 약물을 승인했습니다. 페졸리네탄트라고 불리는 이 처방약은 호르몬 요법을 받을 수 없고 유방암 생존자 등 혈관 운동 증상으로 고통받는 사람들을 위해 특별히 고안된 약물입니다. 이 약은 Veozah라는 브랜드로 판매되고 있습니다.

폐경기 시장 보고서 하이라이트

• 치료법에 따라 2024년에는 식이보충제 치료 분야가 시장을 장악하고 예측 기간 중 가장 빠른 성장을 보일 것으로 예측됩니다. 이 분야의 성장은 노인 인구 증가와 혁신적인 제품 출시 등 여러 요인에 기인하는 것으로 보입니다. 예를 들어 2021년 4월 한국의 건강기능식품 회사인 풀무원은 갱년기 관련 증상 치료를 위해 콩과 홉 추출물을 함유한 제품을 출시했습니다.
• OTC 의약품 치료 부문은 비호르몬성 제품과 호르몬성 제품으로 분류됩니다. 폐경기 여성들은 일반의약품(OTC) 호르몬 제품을 사용하는 경우가 많습니다. 이 부문의 주요 제품으로는 국소 프로게스테론, 이부프로펜, 디하이드로에피안드로스테론(DHEA), 멜라토닌 등이 있습니다.
• 2024년 북미가 가장 큰 매출 점유율을 차지했습니다. 식생활에 대한 인식이 높아지면서 고령 여성들 사이에서 특정 영양 요구에 대한 수요가 증가하고 있습니다.
• 2022년 1월, Amyris, Inc.는 갱년기 치료, 여성 건강 연구, 갱년기 질환에 대한 사회적 이해 증진에 주력하는 여성 창업 기업 MenoLabs, LLC의 자산을 인수하는 독점 계약을 체결했다고 발표했습니다.
• 2023년 1월, 여성 건강 브랜드 오포지티브는 갱년기 여성들이 갱년기 증상을 편리하고 맛있게 관리할 수 있도록 사상 최초의 갱년기 구미 비타민을 출시했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 갱년기 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 갱년기 시장에 대한 COVID-19의 영향에 관한 정성 분석
• 제품 리스트
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 갱년기 장애 시장 부문 분석, 치료별, 2018-2030년

• 갱년기 장애 시장 : 치료별 변동 분석과 시장 점유율
• 갱년기 장애 시장 : 치료별 부문 대시보드
• 식이보충제
• OTC 의약품
  • 호르몬 제품
  • 비호르몬 제품

제5장 지역별, 치료별, 2018-2030년

• 지역 시장 대시보드
• 지역 마켓플레이스 : 주요 포인트
• 북미
  • 북미의 식이보충제 시장
  • 북미의 OTC 의약품 시장
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 식이보충제 시장
  • 유럽의 OTC 의약품 시장
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 오스트리아
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 아시아태평양의 식이보충제 시장
  • 아시아태평양의 OTC 의약품 시장
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
  • 대만
  • 말레이시아
  • 싱가포르
  • 베트남
  • 홍콩
• 라틴아메리카
  • 라틴아메리카의 식이보충제 시장
  • 라틴아메리카의 OTC 의약품 시장
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • MEA 식이보충제 시장
  • MEA OTC 의약품 시장
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제6장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업 분류
• 벤더 구도
• 기업 개요
  • Bayer AG
  • Theramex
  • AbbVie, Inc.
  • Pure Encapsulations, LLC
  • Dr. Reddy's Laboratories Ltd.
  • ReNew Life Holdings Corporation
  • Padagis

KSA

영문 목차

영문목차

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.35 billion by 2030, registering a CAGR of 5.42% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

• Based on treatment, the dietary supplements treatment segment dominated the market in 2024 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
• The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
• North America held the largest revenue share in 2024. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
• In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
• In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Menopause Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. A growing number of women experiencing menopause
    • 3.2.1.2. Increasing awareness regarding the treatment of menopausal symptoms
    • 3.2.1.3. Innovation in products available for the management of Menopause
    • 3.2.1.4. Increasing research supporting the advantages of dietary supplements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Social stigma associated with menopause and adverse effects of products
    • 3.2.2.2. Lack of well-defined regulations
• 3.3. Qualitative Analysis Impact of COVID-19 on Menopause Market
• 3.4. List of Products
• 3.5. Business Environment Analysis
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrants
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis

Chapter 4. Menopause Market Segment Analysis, By Treatment, 2018 - 2030 (USD Million)

• 4.1. Menopause Market: Treatment Movement Analysis and Market Share
• 4.2. Menopause Market: Treatment Segment Dashboard
• 4.3. Dietary Supplements
  • 4.3.1. Dietary supplements market, 2018 - 2030 (USD Million)
• 4.4. OTC Pharma Products
  • 4.4.1. OTC pharma products market, 2018 - 2030 (USD Million)
  • 4.4.2. Hormonal Products
    • 4.4.2.1. Hormonal products market, 2018 - 2030 (USD Million)
  • 4.4.3. Non-hormonal products
    • 4.4.3.1. Non-hormonal products market, 2018 - 2030 (USD Million)

Chapter 5. Region, By Treatment, 2018 - 2030 (USD Million)

• 5.1. Regional Market Dashboard
• 5.2. Regional marketplace: Key takeaways
• 5.3. North America
  • 5.3.1. North America dietary supplements market
    • 5.3.1.1. North America dietary supplements market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3.2. North America OTC pharma products market
    • 5.3.2.1. North America OTC pharma products market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3.3. U.S.
    • 5.3.3.1. U.S. menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.3.3.2. U.S. dietary supplements market
      • 5.3.3.2.1. Regulatory scenario
      • 5.3.3.2.2. Competitive insights
      • 5.3.3.2.3. U.S. dietary supplements market, 2018 - 2030 (USD Million)
    • 5.3.3.3. U.S. OTC pharma products market
      • 5.3.3.3.1. Regulatory scenario
      • 5.3.3.3.2. Competitive insights
      • 5.3.3.3.3. U.S. OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.3.4. Canada
    • 5.3.4.1. Canada menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.3.4.2. Canada dietary supplements market
      • 5.3.4.2.1. Regulatory scenario
      • 5.3.4.2.2. Competitive insights
      • 5.3.4.2.3. Canada dietary supplements market, 2018 - 2030 (USD Million)
    • 5.3.4.3. Canada OTC pharma products market
      • 5.3.4.3.1. Regulatory scenario
      • 5.3.4.3.2. Competitive insights
      • 5.3.4.3.3. Canada OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.3.5. Mexico
    • 5.3.5.1. Mexico menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.3.5.2. Mexico dietary supplements market
      • 5.3.5.2.1. Regulatory scenario
      • 5.3.5.2.2. Competitive insights
      • 5.3.5.2.3. Mexico dietary supplements market, 2018 - 2030 (USD Million)
    • 5.3.5.3. Mexico OTC pharma products market
      • 5.3.5.3.1. Regulatory scenario
      • 5.3.5.3.2. Competitive insights
      • 5.3.5.3.3. Mexico OTC pharma products market, 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. Europe dietary supplements market
    • 5.4.1.1. Europe dietary supplements market estimates and forecast, 2018 - 2030 (USD million)
  • 5.4.2. Europe OTC pharma products market
    • 5.4.2.1. Europe OTC pharma products market estimates and forecast, 2018 - 2030 (USD million)
  • 5.4.3. UK
    • 5.4.3.1. Canada menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.3.2. Canada dietary supplements market
      • 5.4.3.2.1. Regulatory scenario
      • 5.4.3.2.2. Competitive insights
      • 5.4.3.2.3. Canada dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.3.3. Canada OTC pharma products market
      • 5.4.3.3.1. Regulatory scenario
      • 5.4.3.3.2. Competitive insights
      • 5.4.3.3.3. Canada OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.4. Germany
    • 5.4.4.1. Germany menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.4.2. Germany dietary supplements market
      • 5.4.4.2.1. Regulatory scenario
      • 5.4.4.2.2. Competitive insights
      • 5.4.4.2.3. Germany dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.4.3. Germany OTC pharma products market
      • 5.4.4.3.1. Regulatory scenario
      • 5.4.4.3.2. Competitive insights
      • 5.4.4.3.3. Germany OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.5. France
    • 5.4.5.1. France menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.5.2. France dietary supplements market
      • 5.4.5.2.1. Regulatory scenario
      • 5.4.5.2.2. Competitive insights
      • 5.4.5.2.3. France dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.5.3. France OTC pharma products market
      • 5.4.5.3.1. Regulatory scenario
      • 5.4.5.3.2. Competitive insights
      • 5.4.5.3.3. France OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.6. Italy
    • 5.4.6.1. Italy menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.6.2. Italy dietary supplements market
      • 5.4.6.2.1. Regulatory scenario
      • 5.4.6.2.2. Competitive insights
      • 5.4.6.2.3. Italy dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.6.3. Italy OTC pharma products market
      • 5.4.6.3.1. Regulatory scenario
      • 5.4.6.3.2. Competitive insights
      • 5.4.6.3.3. Italy OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.7. Spain
    • 5.4.7.1. Spain menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.7.2. Spain dietary supplements market
      • 5.4.7.2.1. Regulatory scenario
      • 5.4.7.2.2. Competitive insights
      • 5.4.7.2.3. Spain dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.7.3. Spain OTC pharma products market
      • 5.4.7.3.1. Regulatory scenario
      • 5.4.7.3.2. Competitive insights
      • 5.4.7.3.3. Spain OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.8. Austria
    • 5.4.8.1. Austria menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.8.2. Austria dietary supplements market
      • 5.4.8.2.1. Regulatory scenario
      • 5.4.8.2.2. Competitive insights
      • 5.4.8.2.3. Austria dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.8.3. Austria OTC pharma products market
      • 5.4.8.3.1. Regulatory scenario
      • 5.4.8.3.2. Competitive insights
      • 5.4.8.3.3. Austria OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.9. Norway
    • 5.4.9.1. Norway menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.9.2. Norway dietary supplements market
      • 5.4.9.2.1. Regulatory scenario
      • 5.4.9.2.2. Competitive insights
      • 5.4.9.2.3. Norway dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.9.3. Norway OTC pharma products market
      • 5.4.9.3.1. Regulatory scenario
      • 5.4.9.3.2. Competitive insights
      • 5.4.9.3.3. Norway OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.10. Sweden
    • 5.4.10.1. Sweden menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.10.2. Sweden dietary supplements market
      • 5.4.10.2.1. Regulatory scenario
      • 5.4.10.2.2. Competitive insights
      • 5.4.10.2.3. Sweden dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.10.3. Sweden OTC pharma products market
      • 5.4.10.3.1. Regulatory scenario
      • 5.4.10.3.2. Competitive insights
      • 5.4.10.3.3. Sweden OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.4.11. Denmark
    • 5.4.11.1. Denmark menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.4.11.2. Denmark dietary supplements market
      • 5.4.11.2.1. Regulatory scenario
      • 5.4.11.2.2. Competitive insights
      • 5.4.11.2.3. Denmark dietary supplements market, 2018 - 2030 (USD Million)
    • 5.4.11.3. Denmark OTC pharma products market
      • 5.4.11.3.1. Regulatory scenario
      • 5.4.11.3.2. Competitive insights
      • 5.4.11.3.3. Denmark OTC pharma products market, 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Asia Pacific dietary supplements market
    • 5.5.1.1. Asia Pacific dietary supplements market estimates and forecast, 2018 - 2030 (USD million)
  • 5.5.2. Asia Pacific OTC pharma products market
    • 5.5.2.1. Asia Pacific OTC pharma products market estimates and forecast, 2018 - 2030 (USD million)
  • 5.5.3. Japan
    • 5.5.3.1. Japan menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.3.2. Japan dietary supplements market
      • 5.5.3.2.1. Regulatory scenario
      • 5.5.3.2.2. Competitive insights
      • 5.5.3.2.3. Japan dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.3.3. Japan OTC pharma products market
      • 5.5.3.3.1. Regulatory scenario
      • 5.5.3.3.2. Competitive insights
      • 5.5.3.3.3. Japan OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.4. China
    • 5.5.4.1. China menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.4.2. China dietary supplements market
      • 5.5.4.2.1. Regulatory scenario
      • 5.5.4.2.2. Competitive insights
      • 5.5.4.2.3. China dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.4.3. China OTC pharma products market
      • 5.5.4.3.1. Regulatory scenario
      • 5.5.4.3.2. Competitive insights
      • 5.5.4.3.3. China OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.5. India
    • 5.5.5.1. India menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.5.2. India dietary supplements market
      • 5.5.5.2.1. Regulatory scenario
      • 5.5.5.2.2. Competitive insights
      • 5.5.5.2.3. India dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.5.3. India OTC pharma products market
      • 5.5.5.3.1. Regulatory scenario
      • 5.5.5.3.2. Competitive insights
      • 5.5.5.3.3. India OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.6. Australia
    • 5.5.6.1. Australia menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.6.2. Australia dietary supplements market
      • 5.5.6.2.1. Regulatory scenario
      • 5.5.6.2.2. Competitive insights
      • 5.5.6.2.3. Australia dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.6.3. Australia OTC pharma products market
      • 5.5.6.3.1. Regulatory scenario
      • 5.5.6.3.2. Competitive insights
      • 5.5.6.3.3. Australia OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. South Korea menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.7.2. South Korea dietary supplements market
      • 5.5.7.2.1. Regulatory scenario
      • 5.5.7.2.2. Competitive insights
      • 5.5.7.2.3. South Korea dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.7.3. South Korea OTC pharma products market
      • 5.5.7.3.1. Regulatory scenario
      • 5.5.7.3.2. Competitive insights
      • 5.5.7.3.3. South Korea OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.8. Thailand
    • 5.5.8.1. Thailand menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.8.2. Thailand dietary supplements market
      • 5.5.8.2.1. Regulatory scenario
      • 5.5.8.2.2. Competitive insights
      • 5.5.8.2.3. Thailand dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.8.3. Thailand OTC pharma products market
      • 5.5.8.3.1. Regulatory scenario
      • 5.5.8.3.2. Competitive insights
      • 5.5.8.3.3. Thailand OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.9. Taiwan
    • 5.5.9.1. Taiwan menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.9.2. Taiwan dietary supplements market
      • 5.5.9.2.1. Regulatory scenario
      • 5.5.9.2.2. Competitive insights
      • 5.5.9.2.3. Taiwan dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.9.3. Taiwan OTC pharma products market
      • 5.5.9.3.1. Regulatory scenario
      • 5.5.9.3.2. Competitive insights
      • 5.5.9.3.3. Taiwan OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.10. Malaysia
    • 5.5.10.1. Malaysia menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.10.2. Malaysia dietary supplements market
      • 5.5.10.2.1. Regulatory scenario
      • 5.5.10.2.2. Competitive insights
      • 5.5.10.2.3. Malaysia dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.10.3. Malaysia OTC pharma products market
      • 5.5.10.3.1. Regulatory scenario
      • 5.5.10.3.2. Competitive insights
      • 5.5.10.3.3. Malaysia OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.11. Singapore
    • 5.5.11.1. Singapore menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.11.2. Singapore dietary supplements market
      • 5.5.11.2.1. Regulatory scenario
      • 5.5.11.2.2. Competitive insights
      • 5.5.11.2.3. Singapore dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.11.3. Singapore OTC pharma products market
      • 5.5.11.3.1. Regulatory scenario
      • 5.5.11.3.2. Competitive insights
      • 5.5.11.3.3. Singapore OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.12. Vietnam
    • 5.5.12.1. Vietnam menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.12.2. Vietnam dietary supplements market
      • 5.5.12.2.1. Regulatory scenario
      • 5.5.12.2.2. Competitive insights
      • 5.5.12.2.3. Vietnam dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.12.3. Vietnam OTC pharma products market
      • 5.5.12.3.1. Regulatory scenario
      • 5.5.12.3.2. Competitive insights
      • 5.5.12.3.3. Vietnam OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.5.13. Hong Kong
    • 5.5.13.1. Hong Kong menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.5.13.2. Hong Kong dietary supplements market
      • 5.5.13.2.1. Regulatory scenario
      • 5.5.13.2.2. Competitive insights
      • 5.5.13.2.3. Hong Kong dietary supplements market, 2018 - 2030 (USD Million)
    • 5.5.13.3. Hong Kong OTC pharma products market
      • 5.5.13.3.1. Regulatory scenario
      • 5.5.13.3.2. Competitive insights
      • 5.5.13.3.3. Hong Kong OTC pharma products market, 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Latin America dietary supplements market
    • 5.6.1.1. Latin America dietary supplements market estimates and forecast, 2018 - 2030 (USD million)
  • 5.6.2. Latin America OTC pharma products market
    • 5.6.2.1. Latin America OTC pharma products market estimates and forecast, 2018 - 2030 (USD million)
  • 5.6.3. Brazil
    • 5.6.3.1. Brazil menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.6.3.2. Brazil dietary supplements market
      • 5.6.3.2.1. Regulatory scenario
      • 5.6.3.2.2. Competitive insights
      • 5.6.3.2.3. Brazil dietary supplements market, 2018 - 2030 (USD Million)
    • 5.6.3.3. Brazil OTC pharma products market
      • 5.6.3.3.1. Regulatory scenario
      • 5.6.3.3.2. Competitive insights
      • 5.6.3.3.3. Brazil OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.6.4. Argentina
    • 5.6.4.1. Argentina menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.6.4.2. Argentina dietary supplements market
      • 5.6.4.2.1. Regulatory scenario
      • 5.6.4.2.2. Competitive insights
      • 5.6.4.2.3. Argentina dietary supplements market, 2018 - 2030 (USD Million)
    • 5.6.4.3. Argentina OTC pharma products market
      • 5.6.4.3.1. Regulatory scenario
      • 5.6.4.3.2. Competitive insights
      • 5.6.4.3.3. Argentina OTC pharma products market, 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. MEA dietary supplements market
    • 5.7.1.1. MEA dietary supplements market estimates and forecast, 2018 - 2030 (USD million)
  • 5.7.2. MEA OTC pharma products market
    • 5.7.2.1. MEA OTC pharma products market estimates and forecast, 2018 - 2030 (USD million)
  • 5.7.3. South Africa
    • 5.7.3.1. South Africa menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.7.3.2. South Africa dietary supplements market
      • 5.7.3.2.1. Regulatory scenario
      • 5.7.3.2.2. Competitive insights
      • 5.7.3.2.3. South Africa dietary supplements market, 2018 - 2030 (USD Million)
    • 5.7.3.3. South Africa OTC pharma products market
      • 5.7.3.3.1. Regulatory scenario
      • 5.7.3.3.2. Competitive insights
      • 5.7.3.3.3. South Africa OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.7.4. Saudi Arabia
    • 5.7.4.1. Saudi Arabia menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.7.4.2. Saudi Arabia dietary supplements market
      • 5.7.4.2.1. Regulatory scenario
      • 5.7.4.2.2. Competitive insights
      • 5.7.4.2.3. Saudi Arabia dietary supplements market, 2018 - 2030 (USD Million)
    • 5.7.4.3. Saudi Arabia OTC pharma products market
      • 5.7.4.3.1. Regulatory scenario
      • 5.7.4.3.2. Competitive insights
      • 5.7.4.3.3. Saudi Arabia OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.7.5. UAE
    • 5.7.5.1. UAE menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.7.5.2. UAE dietary supplements market
      • 5.7.5.2.1. Regulatory scenario
      • 5.7.5.2.2. Competitive insights
      • 5.7.5.2.3. UAE dietary supplements market, 2018 - 2030 (USD Million)
    • 5.7.5.3. UAE OTC pharma products market
      • 5.7.5.3.1. Regulatory scenario
      • 5.7.5.3.2. Competitive insights
      • 5.7.5.3.3. UAE OTC pharma products market, 2018 - 2030 (USD Million)
  • 5.7.6. Kuwait
    • 5.7.6.1. Kuwait menopausal women target population (45 to 60 years), 2018 - 2023 in millions
    • 5.7.6.2. Kuwait dietary supplements market
      • 5.7.6.2.1. Regulatory scenario
      • 5.7.6.2.2. Competitive insights
      • 5.7.6.2.3. Kuwait dietary supplements market, 2018 - 2030 (USD Million)
    • 5.7.6.3. Kuwait OTC pharma products market
      • 5.7.6.3.1. Regulatory scenario
      • 5.7.6.3.2. Competitive insights
      • 5.7.6.3.3. Kuwait OTC pharma products market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company Categorization
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
• 6.4. Company Profiles
  • 6.4.1. Bayer AG
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Theramex
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. AbbVie, Inc.
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Pure Encapsulations, LLC
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Dr. Reddy's Laboratories Ltd.
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. ReNew Life Holdings Corporation
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Padagis
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives

관련자료